Selectivity of SB203580, SB202190 and Other Commonly Used p38 Inhibitors: Profiling Against a Multi-Enzyme Panel

E-ISSN： 1875-628x|2|7|516-521

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.2, Iss.7, 2005-11, pp. : 516-521

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance

By Baranck M. Bohacova V. Kvackajova J. Hudecova S. Krizanova O. Breier A.

European Journal of Pharmaceutical Sciences, Vol. 14, Iss. 1, 2001-08 ,pp. : 29-36

Elsevier

Access to resources Recommend Favorite

The p38 MAPK Inhibitor SB203580 Blocks Adenosine A₁ Receptor-Induced Attenuation of In Vivo Myocardial Stunning

By Yoshimura Yukihiro Kristo Gentian Keith Byron Jahania Salik Mentzer Robert Lasley Robert

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 6, 2004-11 ,pp. : 433-440

Springer Publishing Company

Access to resources Recommend Favorite

P38 mitogen-activated protein kinase inhibitor SB203580 has a bi-directional effect on iNOS expression and NO production

By Lahti A. Kankaanranta H. Moilanen E.

European Journal of Pharmacology, Vol. 454, Iss. 2, 2002-11 ,pp. : 115-123

Elsevier

Access to resources Recommend Favorite

SB203580 reverses adrenomedullin's effect on proliferation and apoptosis in cultured mesangial cells

By Parameswaran N. Spielman W.S. Brooks D.P. Nambi P.

European Journal of Pharmacology, Vol. 371, Iss. 1, 1999-04 ,pp. : 75-82

Elsevier

Access to resources Recommend Favorite

The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell

Current Pharmaceutical Biotechnology, Vol. 19, Iss. 6, 2018-05 ,pp. : 506-513

Bentham Science Publishers

Access to resources Recommend Favorite